2022
DOI: 10.3389/fonc.2022.951220
|View full text |Cite
|
Sign up to set email alerts
|

Early results of PRO-EPI: PROspective multicenter observational study on elective pelvic nodes irradiation in patients with intermediate/high/very high-risk non-metastatic prostate cancer submitted to radical, adjuvant, or salvage radiotherapy with or without concomitant androgen deprivation therapy

Abstract: Simple Summary: Although radiotherapy plays a fundamental role in the management of intermediate/high/very high-risk non-metastatic prostatic cancer (IHR-nmPca), there is still no consensus on the optimal treatment strategy in this setting. Remarkably, the role of elective nodal irradiation (ENI) is still highly controversial. The PROspective multicenter observational study on Elective Pelvic nodes Irradiation (PRO-EPI) was designed to provide “real life” data regarding the patterns of care for IHR-nmPca.Forty… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 38 publications
(70 reference statements)
0
1
0
Order By: Relevance
“…Consequently, the 2023 National Comprehensive Cancer Network (NCCN) guidelines on RT for high-risk and very-high-risk prostate cancer state that ‘prophylactic nodal radiation should be considered’ ( www.nccn.org ). Therefore, the use of prophylactic WPRT for high-risk prostate cancer will continue to increase [ 3 , 4 ]. In addition, long-term ADT, including neoadjuvant and adjuvant therapy, is commonly used, although definitive conclusions regarding the optimal timing and duration of ADT have not been reached [ 5 ].…”
Section: Introductionmentioning
confidence: 99%
“…Consequently, the 2023 National Comprehensive Cancer Network (NCCN) guidelines on RT for high-risk and very-high-risk prostate cancer state that ‘prophylactic nodal radiation should be considered’ ( www.nccn.org ). Therefore, the use of prophylactic WPRT for high-risk prostate cancer will continue to increase [ 3 , 4 ]. In addition, long-term ADT, including neoadjuvant and adjuvant therapy, is commonly used, although definitive conclusions regarding the optimal timing and duration of ADT have not been reached [ 5 ].…”
Section: Introductionmentioning
confidence: 99%